Compare Amgen, Inc. (AMGN) vs American Water Works Company Inc (AWK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs American Water Works Company Inc — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while American Water Works Company Inc trades at $130.7 (market cap $25.52B). The key difference: Amgen, Inc. is far larger — about 7.7× American Water Works Company Inc's market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | AWK | |
|---|---|---|
Market Cap | $196.12B | $25.52B |
Sector | Health | Utilities |
52-Week High | $388.16 | $147.00 |
52-Week Low | $271.18 | $121.13 |
Enterprise Value | $241.41B | $41.08B |
Dividend Yield | 2.77% | 2.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
American Water Works (AWK) trades at $130.69, up 0.11% with a neutral technical outlook. The stock shows strong fundamentals with consistent revenue growth from $3.8B in 2022 to $5.1B in 2025, maintaining profit margins above 21%. Recent developments include infrastructure investments and regulatory approvals, while analyst consensus leans slightly bullish with a $137 price target.
AWK presents a stable investment opportunity with predictable utility earnings and dividend income. Key risks include regulatory rate approvals and capital expenditure requirements. The stock offers moderate upside potential with balanced analyst sentiment supporting long-term growth in essential water services.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About American Water Works Company Inc
American Water Works is the largest investor-owned U.S. water and wastewater utility, serving approximately 3.5 million customers in 16 states. It provides water and wastewater services to residential, commercial, and industrial customers and operates predominantly in regulated markets. The company's only nonregulated business is water services for military bases, which operates under long-term contracts.
Read more on AWK →
